^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

Published date:
11/01/2017
Excerpt:
Significant synergistic activity was seen in all five BCL-2-positive/SHP1-negative GCB DLBCL cell lines with the R406 + venetoclax combination and in four of them with the ibrutinib + venetoclax combination….Collectively, these findings...identify SHP1 and BCL-2 as potential predictive markers for response to treatment with a venetoclax/BCR inhibitor combination.
DOI:
10.1182/blood-2018-99-118120